News stories about Galectin Therapeutics (NASDAQ:GALT) have trended somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Galectin Therapeutics earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave press coverage about the company an impact score of 47.3478783070455 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Galectin Therapeutics, Inc. (GALT) noted a price change of -3.26% and Pluristem Therapeutics Inc. (PSTI) closes with … – Stocks Gallery (stocksgallery.com)
- Clarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update – GlobeNewswire (press release) (globenewswire.com)
- Pipeline Analysis of Galectin 1 Therapeutic Assessment Covering Drug Profiles Reviewed in H2 2017 (sbwire.com)
- A Look at this Riveting Stock: Galectin Therapeutics, Inc. (NASDAQ:GALT) – FLBC News (flbcnews.com)
Galectin Therapeutics (GALT) traded up 1.12% during trading on Friday, reaching $1.80. The company had a trading volume of 51,134 shares. The company has a 50-day moving average price of $2.13 and a 200 day moving average price of $2.24. The company’s market capitalization is $63.09 million. Galectin Therapeutics has a one year low of $0.49 and a one year high of $3.68.
Galectin Therapeutics (NASDAQ:GALT) last released its earnings results on Monday, August 14th. The company reported ($0.14) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.01. During the same quarter in the prior year, the company earned ($0.20) EPS. Analysts expect that Galectin Therapeutics will post ($0.56) earnings per share for the current year.
Several equities analysts have recently weighed in on GALT shares. Zacks Investment Research upgraded Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a report on Tuesday, June 13th. ValuEngine cut Galectin Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the stock. Galectin Therapeutics has an average rating of “Hold” and an average target price of $2.25.
ILLEGAL ACTIVITY WARNING: “Galectin Therapeutics (GALT) Receiving Somewhat Favorable Press Coverage, Study Finds” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://sportsperspectives.com/2017/08/20/galectin-therapeutics-galt-receiving-somewhat-favorable-press-coverage-study-finds.html.
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.